AUTHORS
Shrinkhala Khanna, MD, Yana Salei, MD2, Taylor Francoeur Smith, MD3, Andrea Zhu, N/A4
AFFILIATIONS
1 UMass Chan Medical School, Worcester, Massachusetts, United States
2 UMass Chan Medical School, Worcester, Massachusetts, United States
3 UMass Chan Medical School, Worcester, Massachusetts, United States
4 UMass Chan Medical School, Worcester, Massachusetts, United States
ABSTRACT
Introduction: Shiga toxin-associated hemolytic uremic syndrome (ST-HUS) is the most common form of hemolytic uremic syndrome (HUS), predominantly affecting children and much rarer in adults.Its estimated incidence in the United States in those <5 years of age is 0.85/100,000; compared to an incidence of 0.01/100,000 in ages 18-59 years and 0.04/100,000 in ≥60 years. Treatment is mainly supportive, and antibiotics are avoided as they increase shiga toxin release and worsen outcomes. The pathogenesis is related to thrombotic microangiopathy (TMA) characterized by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury, typically occurring 5-10 days after an episode of bloody diarrhea. In severe ST-HUS cases, unregulated activation of the complement pathway leads to severe organ damage. Eculizumab is a humanized monoclonal antibody that binds C5, preventing terminal complement activation. We report two similar cases that presented within an 18-month period, with severe, multi-organ ST-HUS and had remarkable recovery after 1-3 doses of eculizumab.
Case Presentations: A 70 y old lady with hypertension and diabetes presented with bloody diarrhea and abdominal pain. Labs showed a white blood cell count of 21.6 x 103/uL, Hgb 12.7 g/dL, platelets 245 x 103/uL, creatinine 1.04 mg/dL (with a known baseline of 0.6 mg/dL) and imaging showed colitis. She was started on empiric treatment with antibiotics for colitis. She then became obtunded and needed intubation and developed worsening acute kidney injury (AKI) and MAHA with schistocytes. She required dialysis, initial stool sample was not available- so she received one dose of eculizumab for presumed aHUS. Within a few days, her mental status improved but she continued to need dialysis. Ultimately, Shiga toxin testing was able to be obtained and was positive.
Case 2 was a 73-y old lady with pulmonary sarcoidosis and atrial fibrillation, who presented with 4 days of bloody diarrhea, and received antibiotics for typhlitis on imaging. On day 3,she became obtunded needing intubation,developed worsening MAHA and AKI, with smear showing 3-5 schistocytes/HPF. Stool was positive for Shiga toxin. She then needed dialysis and suffered a pulseless electrical activity (PEA) arrest. ADAMTS13 was 65%. Because of clinical worsening, eculizumab was started on hospital day 13, and she received a total of 3 doses along with meningococcal vaccination and antibiotic prophylaxis. She was extubated six days following the first dose. By discharge, her hemolysis, encephalopathy and renal failure had resolved.
Discussion: Eculizumab acts by binding to the complement protein C5 at the beginning of the terminal pathway, inhibiting the formation of the membrane attack complex (C5b-C9), protecting cells from lysis without affecting earlier immune functions like C3 opsonization. There is a continuum between severe ST-HUS with neurological features and aHUS, as the fulminant endothelial damage in ST-HUS can trigger complement mediated organ injury, which explains why eculizumab might be life-saving in such cases.
Our case series highlights several unique findings. Both the patients were women in their 70s, and presented within an 18-month period. Their condition rapidly deteriorated with life threatening multi-organ failure. They received antibiotics for colitis before ST-HUS was confirmed, which could have worsened outcomes as shown in several studies, due to an increase in systemic Shiga toxin. They had remarkable recovery soon after their first dose of eculizumab. There is evidence to show that some patients with underlying complement function defects might be more susceptible to neurological complications from ST-HUS. The most common mutations are found in complement regulatory genes (CFH, CFI, MCP/CD46) and activation genes (C3, CFB). The limitation of our case series is that we could not perform genetic testing such as Next Generation Sequencing (NGS) to look for these mutations in our two cases.We plan to establish a TMA registry at our institution which serves a large population in central Massachusetts, Connecticut, and New Hampshire. This registry would serve to collect prospective information on the management and outcomes of our TMA patients. We aim to apply for a research grant to perform genetic testing for complement and other mutations in these patients, to identify any links with genetic susceptibility to severe ST-HUS presentation.
DISCLOSURES
Shrinkhala Khanna, MD: No relevant conflicts of interest to declare.